Despite recent advances in the field of medical and radiation oncology, and the introduction of neoadjuvant and adjuvant regimens, surgery remains the single most important modality for the treatment of pancreatic ductal adenocarcinoma. This Review discusses the technical improvements that have made pancreatic surgery safe, with low morbidity and mortality rates in tertiary referral centers, and it highlights the challenges of surgical palliation.
- Christoph W Michalski
- Jürgen Weitz
- Markus W Büchler
